Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer

Ulka N. Vaishampayan; Joseph Fontana; Lance K. Heilbrun; Daryn Smith; Elisabeth Heath; Brenda Dickow; William D. Figg

doi:10.1016/j.urolonc.2012.11.017

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer

Ulka N. Vaishampayan^*, Joseph Fontana, Lance K. Heilbrun, Daryn Smith, Elisabeth Heath, Brenda Dickow, William D. Figg

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background: Satraplatin is an oral platinum compound that has demonstrated efficacy and tolerability in prostate cancer. Preclinical synergy between bevacizumab and platinum has been noted. Methods: Docetaxel-pretreated metastatic castrate-resistant prostate cancer patients with disease progression were eligible. Satraplatin 80mg/m² orally on days 1 to 5, prednisone 5mg twice daily, and bevacizumab 10mg/kg on day 1, and 15mg/kg on day 15 were administered in 35-day cycles. Results: Thirty one patients were enrolled. Grade 3 or 4 toxicities were pulmonary embolism in 2 patients and thrombocytopenia in 1 patient. 31% of the patients had a≥30% decline in prostate-specific antigen. Median time to progression was 7.0 months (90% confidence interval [CI] 4.7-8.5. mo) and median overall survival was 11.2 months (90% CI 9.1-16.4. mo). Polymorphism in the excision repair cross-complementation-1 (ERCC-1) gene was associated with time to progression (hazard ratio = 1.91). A circulating tumor cell count≥5was moderately prognostic of overall survival (hazard ratio = 1.49) as compared with CTC <5. Conclusions: The combination was tolerable, and revealed promising efficacy in metastatic castrate-resistant prostate cancer. ERCC1 genotype maybe predictive of clinical benefit with platinum-based therapy in metastatic prostate cancer.

Original language	English
Pages (from-to)	31.e25-31.e33
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	32
Issue number	1
DOIs	https://doi.org/10.1016/j.urolonc.2012.11.017
State	Published - Jan 2014
Externally published	Yes

Keywords

Chemotherapy
Excision repair polymorphism
Phase II clinical trial
Prostate cancer

Access to Document

10.1016/j.urolonc.2012.11.017

Cite this

@article{f64918b116a9444d8666f58e1ebbe793,

title = "Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer",

abstract = "Background: Satraplatin is an oral platinum compound that has demonstrated efficacy and tolerability in prostate cancer. Preclinical synergy between bevacizumab and platinum has been noted. Methods: Docetaxel-pretreated metastatic castrate-resistant prostate cancer patients with disease progression were eligible. Satraplatin 80mg/m2 orally on days 1 to 5, prednisone 5mg twice daily, and bevacizumab 10mg/kg on day 1, and 15mg/kg on day 15 were administered in 35-day cycles. Results: Thirty one patients were enrolled. Grade 3 or 4 toxicities were pulmonary embolism in 2 patients and thrombocytopenia in 1 patient. 31% of the patients had a≥30% decline in prostate-specific antigen. Median time to progression was 7.0 months (90% confidence interval [CI] 4.7-8.5. mo) and median overall survival was 11.2 months (90% CI 9.1-16.4. mo). Polymorphism in the excision repair cross-complementation-1 (ERCC-1) gene was associated with time to progression (hazard ratio = 1.91). A circulating tumor cell count≥5was moderately prognostic of overall survival (hazard ratio = 1.49) as compared with CTC <5. Conclusions: The combination was tolerable, and revealed promising efficacy in metastatic castrate-resistant prostate cancer. ERCC1 genotype maybe predictive of clinical benefit with platinum-based therapy in metastatic prostate cancer.",

keywords = "Chemotherapy, Excision repair polymorphism, Phase II clinical trial, Prostate cancer",

author = "Vaishampayan, {Ulka N.} and Joseph Fontana and Heilbrun, {Lance K.} and Daryn Smith and Elisabeth Heath and Brenda Dickow and Figg, {William D.}",

note = "Funding Information: This work was supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. The views expressed within this paper do not necessarily reflect those of the US Government.",

year = "2014",

month = jan,

doi = "10.1016/j.urolonc.2012.11.017",

language = "English",

volume = "32",

pages = "31.e25--31.e33",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

number = "1",

}

TY - JOUR

T1 - Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer

AU - Vaishampayan, Ulka N.

AU - Fontana, Joseph

AU - Heilbrun, Lance K.

AU - Smith, Daryn

AU - Heath, Elisabeth

AU - Dickow, Brenda

AU - Figg, William D.

N1 - Funding Information: This work was supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. The views expressed within this paper do not necessarily reflect those of the US Government.

PY - 2014/1

Y1 - 2014/1

N2 - Background: Satraplatin is an oral platinum compound that has demonstrated efficacy and tolerability in prostate cancer. Preclinical synergy between bevacizumab and platinum has been noted. Methods: Docetaxel-pretreated metastatic castrate-resistant prostate cancer patients with disease progression were eligible. Satraplatin 80mg/m2 orally on days 1 to 5, prednisone 5mg twice daily, and bevacizumab 10mg/kg on day 1, and 15mg/kg on day 15 were administered in 35-day cycles. Results: Thirty one patients were enrolled. Grade 3 or 4 toxicities were pulmonary embolism in 2 patients and thrombocytopenia in 1 patient. 31% of the patients had a≥30% decline in prostate-specific antigen. Median time to progression was 7.0 months (90% confidence interval [CI] 4.7-8.5. mo) and median overall survival was 11.2 months (90% CI 9.1-16.4. mo). Polymorphism in the excision repair cross-complementation-1 (ERCC-1) gene was associated with time to progression (hazard ratio = 1.91). A circulating tumor cell count≥5was moderately prognostic of overall survival (hazard ratio = 1.49) as compared with CTC <5. Conclusions: The combination was tolerable, and revealed promising efficacy in metastatic castrate-resistant prostate cancer. ERCC1 genotype maybe predictive of clinical benefit with platinum-based therapy in metastatic prostate cancer.

AB - Background: Satraplatin is an oral platinum compound that has demonstrated efficacy and tolerability in prostate cancer. Preclinical synergy between bevacizumab and platinum has been noted. Methods: Docetaxel-pretreated metastatic castrate-resistant prostate cancer patients with disease progression were eligible. Satraplatin 80mg/m2 orally on days 1 to 5, prednisone 5mg twice daily, and bevacizumab 10mg/kg on day 1, and 15mg/kg on day 15 were administered in 35-day cycles. Results: Thirty one patients were enrolled. Grade 3 or 4 toxicities were pulmonary embolism in 2 patients and thrombocytopenia in 1 patient. 31% of the patients had a≥30% decline in prostate-specific antigen. Median time to progression was 7.0 months (90% confidence interval [CI] 4.7-8.5. mo) and median overall survival was 11.2 months (90% CI 9.1-16.4. mo). Polymorphism in the excision repair cross-complementation-1 (ERCC-1) gene was associated with time to progression (hazard ratio = 1.91). A circulating tumor cell count≥5was moderately prognostic of overall survival (hazard ratio = 1.49) as compared with CTC <5. Conclusions: The combination was tolerable, and revealed promising efficacy in metastatic castrate-resistant prostate cancer. ERCC1 genotype maybe predictive of clinical benefit with platinum-based therapy in metastatic prostate cancer.

KW - Chemotherapy

KW - Excision repair polymorphism

KW - Phase II clinical trial

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84890794855&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2012.11.017

DO - 10.1016/j.urolonc.2012.11.017

M3 - Article

C2 - 23433892

AN - SCOPUS:84890794855

SN - 1078-1439

VL - 32

SP - 31.e25-31.e33

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 1

ER -

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this